NSC-EVs — Neural Stem Cell-Derived Exosomes for Early-Onset Alzheimer's Disease, Phase 1
—
| Trial ID | NCT07554872 ↗ |
|---|---|
| Sponsor | Shanghai Mental Health Center · China |
| Cell Source | 신경줄기세포 (NSC) · allogeneic |
| Indication | 알츠하이머병 · Alzheimer's Disease |
| Phase | PHASE 1 |
| Status | NOT-YET-RECRUITING |
| Delivery Route | intranasal |
| Enrollment | 9 |
| Publication | — |
Trial Design
This is an open-label, single-centre Phase 1 clinical trial evaluating the safety, tolerability, and preliminary efficacy of neural stem cell-derived exosomes (NSC-EVs) in patients with moderate-to-severe early-onset Alzheimer’s disease.
Nine participants are enrolled into three frequency-escalation groups, receiving NSC-EVs every three days, every other day, or daily, with all groups receiving treatment for 28 days. Follow-up continues at 4, 8, and 24 weeks after treatment completion.
The primary endpoint is treatment-related adverse events and laboratory abnormalities. Secondary endpoints include changes in the Chinese Mini-Mental Status Examination, Severe Impairment Battery, Neuropsychiatric Inventory, and Geriatric Depression Scale.
Clinical Significance
This study uses neural stem cell-derived exosomes — rather than the cells themselves — for Alzheimer’s disease. Because cell transplantation in neurological conditions raises significant concerns around safety, engraftment, and positional control, cell-derived EVs are being explored as a potential cell-free alternative.
The intranasal delivery route is also noteworthy. In central nervous system conditions, intranasal administration is under investigation as a less invasive route with the potential for direct CNS delivery.
Reasons NSC-EVs are drawing attention:
- Neural stem cell-derived EVs — cell-derived material specific to the neurological context
- Cell-free therapeutic approach — potentially lower safety burden than cell transplantation
- Intranasal delivery — a non-invasive route targeting CNS delivery
- Alzheimer’s disease indication — a neurodegenerative condition with limited therapeutic options
Limitations and Discussion
With only nine participants in an open-label design, the ability to draw conclusions about efficacy is severely limited. The clinical trajectory of Alzheimer’s disease is subject to considerable natural variability, making controlled follow-up studies essential. The composition of NSC-EVs, potency, blood-brain barrier penetration, and the safety of repeated administration are all key questions that remain to be resolved.